Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers. RC010 is a small-molecule drug , being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability and pharmacokinetics of RC010 after Single ascending doses .

Participants needed: 42
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Nanjing Reju Therapeutics Co., LtdUpdated: Apr 14, 2026Locations: 1
Eligibility criteria

Be able to communicate well with the researchers, fully understand the objective... [+3]

Received clinical trial medication or participated in other medical research act... [+26]

Status: Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants

This is a Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of RC017 Ophthalmic Ointment Following Single and Multiple Doses in Healthy Adult Participants.RC017 is a small-molecule drug, being developed as a novel therapeutic treatment for patients with Dry Eye Disease (DED) . This study aims to evaluate the safety, tolerability and pharmacokinetics of RC017 after Single and Multiple Doses.

Participants needed: 24
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Nanjing Reju Therapeutics Co., LtdUpdated: Apr 13, 2026
Eligibility criteria

Healthy male and female trial participants aged 18 to 55 years old (inclusive); [+4]

History of ocular diseases deemed by the investigator as unsuitable for enrollme... [+15]